A groundbreaking study published in Nature Medicine, has identified a shocking link between picloram, a widely used herbicide, and a dramatic rise in early-onset colorectal cancer among Americans under 50. The findings, which trace decades of agricultural exposure to this chemical, could redefine public health strategies to combat a growing crisis.
Colorectal cancer, once predominantly diagnosed in older adults, has become the leading cause of cancer death in men under 50 and the second-deadliest in women under 50, according to the American Cancer Society. Despite declining rates in those over 65, incidence among younger populations has surged. Researchers puzzled over this trend until the 2026 study revealed a startling connection: epigenetic changes linked to picloram exposure in young patients.
The team analyzed epigenetic methylation patterns in tumor DNA from 20 high-risk subjects and cross-referenced data from The Cancer Genome Atlas and nine independent patient groups. Epigenetic marks, which alter gene expression without changing DNA sequences, revealed a chemical signature unique to early-onset cases. This signature was absent in patients diagnosed after 50.
Key finding: Picloram, a broadleaf herbicide in use since 1963, showed a 98% correlation with early-onset colorectal cancer. County-level data from the National Cancer Institute and U.S. Geological Survey confirmed that regions with heavy picloram use had higher cancer rates, even after adjusting for demographics and other pesticides.
Unlike traditional genetic mutations, picloram appears to trigger cancer through epigenetic disruption. The herbicide accumulates in agricultural environments and leaves lasting chemical marks on DNA, promoting abnormal cell growth in the colon.
Dr. Jonathan Landsman, lead author of the study, explained: "This isn't a random mutation, it's a pattern of exposure. For decades, picloram has been sprayed on crops, seeping into soil and water. Now, it's showing up in the DNA of young patients. This is modifiable. We can act now."
Picloram's widespread use since the green revolution of the 1960s aligns with the rise in early-onset cancer cases. As Landsman noted: "The cancer risk isn't new, it's been hiding in plain sight. We've known about picloram's persistence for years, but no one connected it to this epidemic."
The study's implications are staggering. Conventional screening, which begins at age 50, fails to address this upstream environmental risk. Meanwhile, picloram remains legally approved for use in the U.S., despite its newly confirmed link to cancer.
The research team emphasizes actionable steps to reduce risk:
The findings challenge the status quo in oncology, which focuses on genetic testing and late-stage interventions. As Landsman argues, "This is about prevention. We've ignored environmental factors for decades, and now we're paying the price."
Critics note that regulatory agencies like the EPA and FDA, which have ties to agrochemical companies, may resist banning picloram despite its risks. Meanwhile, the Natural News article highlights public demand for transparency, stating: "The truth is out there. Now, the question is whether policymakers will act."
As noted by BrightU.AI's Enoch, the 2026 study offers hope: epigenetic damage is reversible with early intervention. By reducing exposure, supporting detox pathways and advocating for policy change, individuals can combat this preventable crisis.
Watch this video about colonoscopy and colorectal cancer screening.
This video is from the Wellness Forum Health channel on Brighteon.com.
Sources include: